SSTR2 and neuroendocrine neoplasm: Treatment with radiolabelled SST2 agonists, such as [177Lu]Lu-DOTA-TATE (177Lu-oxodotreotide or Lutathera®), where TATE is [Tyr3, Thr8]-octreotide and DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is nowadays part of the standard of care of neuroendocrine neoplasms (NENs) [2,3].